



Lilly Cares® Foundation 2025 State-Level Results

Diabetes Medications

BAQSIMI® (glucagon) nasal powder; Basaglar® (insulin glargine injection); Humalog® (insulin lispro injection); Humulin® (human insulin); Lyumjev® (insulin lispro-aabc) injection; Trulicity® (dulaglutide) injection

	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$240,000	36
AL	\$19,600,000	2,595
AR	\$7,100,000	787
AZ	\$11,200,000	1,211
CA	\$21,800,000	2,334
CO	\$7,100,000	733
CT	\$3,400,000	416
DC	\$180,000	21
DE	\$2,900,000	300
FL	\$42,900,000	5,212
GA	\$33,300,000	4,485
HI	\$490,000	51
IA	\$8,800,000	911
ID	\$6,100,000	627
IL	\$26,800,000	3,020
IN	\$44,500,000	4,738
KS	\$13,000,000	1,451
KY	\$17,300,000	1,975
LA	\$15,800,000	1,629
MA	\$10,400,000	1,003
MD	\$13,000,000	1,539
ME	\$5,100,000	581
MI	\$51,700,000	4,846
MN	\$15,900,000	1,648
MO	\$25,200,000	2,649
MS	\$8,900,000	963
MT	\$3,500,000	349
NC	\$53,900,000	6,198
ND	\$1,500,000	169
NE	\$10,400,000	1,090
NH	\$5,500,000	583
NJ	\$9,600,000	1,244
NM	\$2,800,000	288
NV	\$5,800,000	606
NY	\$22,500,000	2,357
OH	\$66,400,000	6,861
OK	\$14,500,000	1,671
OR	\$7,400,000	768
PA	\$40,400,000	4,253
PR	\$270,000	29
RI	\$4,200,000	469
SC	\$19,300,000	2,051
SD	\$2,400,000	264
TN	\$34,800,000	3,791
TX	\$91,100,000	10,540
UT	\$12,200,000	1,409
VA	\$34,300,000	4,707
VI	\$20,000	2
VT	\$670,000	69
WA	\$10,900,000	1,225
WI	\$28,900,000	2,812
WV	\$8,700,000	902
WY	\$1,700,000	227

Basaglar®, Humalog®, Humulin®, Lyumjev® and Trulicity® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates. BAQSIMI® is a registered trademark of its owner.

Lilly Cares® Foundation 2025 State-Level Results

Neuroscience Medications [Mental Health, Migraine, Alzheimer's Disease]

Cymbalta® (duloxetine delayed-release capsules); Emgality® (galcanezumab-gnlm) injection; Kisunla® (donanemab-azbt) injection; Prozac® (fluoxetine); REYVOW® (lasmiditan); Strattera® (atomoxetine)

	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$20,000	2
AL	\$1,300,000	166
AR	\$640,000	87
AZ	\$1,100,000	132
CA	\$1,300,000	157
CO	\$1,200,000	144
CT	\$370,000	44
DC	\$10,000	1
DE	\$140,000	15
FL	\$5,100,000	644
GA	\$2,300,000	322
IA	\$990,000	116
ID	\$410,000	51
IL	\$1,100,000	157
IN	\$1,600,000	218
KS	\$560,000	76
KY	\$1,800,000	240
LA	\$590,000	77
MA	\$330,000	38
MD	\$590,000	74
ME	\$230,000	27
MI	\$2,100,000	278
MN	\$830,000	103
MO	\$1,700,000	206
MS	\$820,000	112
MT	\$280,000	40
NC	\$2,500,000	325
ND	\$140,000	20
NE	\$420,000	51
NH	\$530,000	63
NJ	\$780,000	87
NM	\$200,000	23
NV	\$390,000	38
NY	\$1,100,000	145
OH	\$1,800,000	233
OK	\$700,000	86
OR	\$470,000	60
PA	\$2,600,000	320
PR	\$50,000	8
RI	\$60,000	7
SC	\$1,100,000	145
SD	\$310,000	45
TN	\$2,000,000	266
TX	\$4,100,000	558
UT	\$470,000	56
VA	\$1,800,000	225
VT	\$150,000	17
WA	\$1,000,000	129
WI	\$1,400,000	177
WV	\$490,000	59
WY	\$240,000	36

Cymbalta®, Emgality®, Kisunla®, Prozac®, REYVOW®, and Strattera® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

Lilly Cares® Foundation 2025 State-Level Results

Cancer Medications

Alimta® (pemetrexed for injection); Cyramza® (ramucirumab) injection; Erbitux® (cetuximab) injection; Inluriyo™ (imlunestrant)
Jaypirca® (pirtobrutinib); Retevmo® (selpercatinib); Verzenio® (abemaciclib)

	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$1,200,000	11
AL	\$12,300,000	118
AR	\$10,900,000	97
AZ	\$35,000,000	245
CA	\$61,800,000	465
CO	\$19,200,000	157
CT	\$10,500,000	81
DC	\$940,000	6
DE	\$3,600,000	25
FL	\$96,800,000	783
GA	\$42,200,000	355
HI	\$2,200,000	19
IA	\$9,000,000	62
ID	\$5,800,000	47
IL	\$41,100,000	326
IN	\$20,000,000	164
KS	\$13,100,000	103
KY	\$12,000,000	99
LA	\$11,100,000	92
MA	\$17,700,000	139
MD	\$16,700,000	143
ME	\$3,900,000	37
MI	\$24,800,000	183
MN	\$14,400,000	125
MO	\$17,900,000	170
MS	\$13,900,000	104
MT	\$4,100,000	27
NC	\$39,600,000	330
ND	\$2,000,000	15
NE	\$5,500,000	48
NH	\$4,500,000	31
NJ	\$37,600,000	290
NM	\$5,000,000	37
NV	\$7,700,000	62
NY	\$36,400,000	270
OH	\$52,600,000	419
OK	\$9,600,000	77
OR	\$14,500,000	104
PA	\$43,900,000	324
PR	\$720,000	8
RI	\$4,100,000	23
SC	\$16,200,000	155
SD	\$1,000,000	13
TN	\$27,800,000	226
TX	\$147,700,000	1,184
UT	\$5,900,000	53
VA	\$41,500,000	312
VI	\$130,000	2
VT	\$1,300,000	10
WA	\$25,200,000	188
WI	\$29,900,000	219
WV	\$8,500,000	63
WY	\$2,100,000	14

Alimta®, Cyramza®, Erbitux®, Jaypirca®, Retevmo® and Verzenio® are registered trademarks and Inluriyo™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

Lilly Cares® Foundation 2025 State-Level Results

Immune Disorder Medications

Ebglyss® (lebrikizumab-lbkz) injection; Olumiant® (baricitinib); Taltz® (ixekizumab) injection

	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$1,500,000	22
AL	\$27,400,000	407
AR	\$42,000,000	631
AZ	\$18,900,000	285
CA	\$40,500,000	606
CO	\$15,300,000	244
CT	\$7,400,000	119
DC	\$110,000	3
DE	\$4,100,000	60
FL	\$86,300,000	1,319
GA	\$40,600,000	609
HI	\$4,400,000	77
IA	\$8,000,000	112
ID	\$12,000,000	180
IL	\$33,000,000	497
IN	\$39,600,000	557
KS	\$13,600,000	203
KY	\$16,000,000	232
LA	\$21,200,000	314
MA	\$12,700,000	179
MD	\$10,100,000	149
ME	\$4,800,000	65
MI	\$39,400,000	598
MN	\$18,500,000	248
MO	\$32,900,000	451
MS	\$8,800,000	124
MT	\$4,300,000	65
NC	\$38,500,000	586
ND	\$3,900,000	50
NE	\$8,200,000	114
NH	\$5,400,000	85
NJ	\$25,500,000	356
NM	\$3,600,000	51
NV	\$6,800,000	112
NY	\$35,200,000	494
OH	\$45,500,000	652
OK	\$21,300,000	311
OR	\$12,400,000	183
PA	\$36,100,000	493
PR	\$1,900,000	31
RI	\$2,900,000	37
SC	\$21,300,000	325
SD	\$3,700,000	62
TN	\$39,500,000	614
TX	\$112,900,000	1,728
UT	\$11,900,000	182
VA	\$22,600,000	337
VT	\$1,200,000	21
WA	\$20,100,000	297
WI	\$16,500,000	234
WV	\$7,100,000	94
WY	\$1,800,000	26

Taltz®, Ebglyss®, their delivery device base, and Olumiant® are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

Lilly Cares® Foundation 2025 State-Level Results

Women's, Men's, and Children's Health Medications

Cialis® (tadalafil); Evista® (raloxifene hydrochloride); Forteo® (teriparatide injection); Humatrope® (somatropin) for injection

	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$310,000	7
AL	\$5,100,000	217
AR	\$2,800,000	75
AZ	\$4,200,000	124
CA	\$17,200,000	495
CO	\$6,400,000	161
CT	\$1,500,000	40
DC	\$50,000	1
DE	\$910,000	26
FL	\$20,300,000	1,076
GA	\$5,700,000	233
HI	\$200,000	5
IA	\$3,600,000	101
ID	\$3,500,000	97
IL	\$7,700,000	214
IN	\$11,700,000	321
KS	\$1,600,000	48
KY	\$3,500,000	121
LA	\$4,800,000	145
MA	\$3,600,000	89
MD	\$2,000,000	53
ME	\$1,300,000	40
MI	\$4,700,000	144
MN	\$5,900,000	152
MO	\$11,800,000	305
MS	\$2,300,000	115
MT	\$2,000,000	57
NC	\$7,900,000	289
ND	\$1,700,000	41
NE	\$1,900,000	53
NH	\$1,700,000	41
NJ	\$6,200,000	160
NM	\$1,200,000	35
NV	\$990,000	42
NY	\$7,600,000	218
OH	\$14,400,000	382
OK	\$4,000,000	121
OR	\$2,400,000	64
PA	\$11,900,000	352
PR	\$480,000	11
RI	\$950,000	27
SC	\$7,600,000	211
SD	\$2,000,000	36
TN	\$5,800,000	181
TX	\$21,900,000	801
UT	\$2,400,000	66
VA	\$5,600,000	200
VI	\$30,000	1
VT	\$510,000	16
WA	\$6,200,000	159
WI	\$8,900,000	226
WV	\$2,200,000	59
WY	\$460,000	14

Cialis®, Evista®, Forteo® and Humatrope® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

Lilly Cares Foundation, Inc., Lilly Corporate Center, Indianapolis, IN 46285; Dan Collins, d.collins@lilly.com